Kyverna Therapeutics sees cash and securities sufficient into 2027

Kyverna reported $286.0M in cash, cash equivalents, and available-for-sale marketable securities as of December 31, 2024. The company expects this to provide a cash runway into 2027, which is sufficient to achieve key inflection points across its priority indications.